The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
The FDA has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use...
The European Commission has approved the once-daily angiotensin receptor blocker (ARB) Edarbi (azilsartan medoxomil) from Takeda for Essential Hypertension. The...